{"id":"matching-placebo-b","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It is designed to mimic the appearance and administration of the active drug, allowing researchers to compare the effects of the active drug to a neutral baseline. This is particularly useful in phase 3 trials where the efficacy of the active drug is being evaluated.","oneSentence":"Matching Placebo (B) is a pharmacologically inert substance used as a control in clinical trials.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:20:11.138Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT06972446","phase":"PHASE2","title":"A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis","status":"RECRUITING","sponsor":"AbbVie","startDate":"2025-06-20","conditions":"Rheumatoid Arthritis","enrollment":180},{"nctId":"NCT05531565","phase":"PHASE2, PHASE3","title":"A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus","status":"RECRUITING","sponsor":"Biogen","startDate":"2022-09-13","conditions":"Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus","enrollment":450},{"nctId":"NCT04849728","phase":"PHASE3","title":"A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )","status":"ACTIVE_NOT_RECRUITING","sponsor":"Inventiva Pharma","startDate":"2021-08-19","conditions":"NASH - Nonalcoholic Steatohepatitis","enrollment":1000},{"nctId":"NCT05564390","phase":"PHASE2","title":"MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-18","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":2000},{"nctId":"NCT06980428","phase":"PHASE1","title":"A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants With Dyslipidemia","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-05-27","conditions":"Healthy Participants, Dyslipidemia","enrollment":136},{"nctId":"NCT07363694","phase":"PHASE2, PHASE3","title":"A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease","status":"RECRUITING","sponsor":"Pfizer","startDate":"2026-02-11","conditions":"Moderate to Severe Chronic Obstructive Pulmonary Disease","enrollment":1156},{"nctId":"NCT07022119","phase":"PHASE1","title":"A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants","status":"COMPLETED","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2025-06-12","conditions":"Autosomal Dominant Polycystic Kidney Disease (ADPKD)","enrollment":32},{"nctId":"NCT04297683","phase":"PHASE2, PHASE3","title":"HEALEY ALS Platform Trial - Master Protocol","status":"RECRUITING","sponsor":"Merit E. Cudkowicz, MD","startDate":"2020-06-14","conditions":"Amyotrophic Lateral Sclerosis","enrollment":1500},{"nctId":"NCT06975722","phase":"PHASE2","title":"A Study to Investigate the Efficacy and Safety of SAR442970 in Adult Participants With Ulcerative Colitis","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-07-07","conditions":"Ulcerative Colitis","enrollment":99},{"nctId":"NCT06154447","phase":"PHASE1","title":"Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis","status":"RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2023-12-12","conditions":"Cystic Fibrosis","enrollment":255},{"nctId":"NCT07250048","phase":"PHASE1","title":"A Study in Healthy Men to Find Out How Different Doses of BI 3009947 Are Tolerated and How Different Formulations or Food Influence How BI 3009947 is Taken up Into the Blood","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2025-11-21","conditions":"Healthy","enrollment":40},{"nctId":"NCT07144293","phase":"PHASE2","title":"Improving Physical Ability and Cellular Senescence Elimination in HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-12-04","conditions":"HIV, Frailty, Prefrail","enrollment":82},{"nctId":"NCT07489599","phase":"PHASE1","title":"A Study of QLH2405 in Healthy Participants and Participants With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2026-03","conditions":"Alzheimer's Disease(AD), Mild Cognitive Impairment (MCI)","enrollment":68},{"nctId":"NCT05312879","phase":"PHASE2, PHASE3","title":"Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease","status":"RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2022-03-30","conditions":"Proteinuric Kidney Disease","enrollment":466},{"nctId":"NCT07388667","phase":"PHASE1","title":"A Clinical Study of MK-4082 in Healthy Overweight Participants (MK-4082-002)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-03-04","conditions":"Healthy","enrollment":120},{"nctId":"NCT07225569","phase":"PHASE2","title":"A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-12-29","conditions":"Hidradenitis Suppurativa","enrollment":144},{"nctId":"NCT07300514","phase":"PHASE3","title":"Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-03-30","conditions":"Maintenance Treatment of Peripheral T-cell Lymphoma","enrollment":136},{"nctId":"NCT01946204","phase":"PHASE3","title":"A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Aragon Pharmaceuticals, Inc.","startDate":"2013-10-14","conditions":"Prostatic Neoplasms","enrollment":1207},{"nctId":"NCT07412691","phase":"PHASE1","title":"A Study to Evaluate the Safety of BG-A3004 in Healthy Participants and Patients With Immune-Mediated Skin Diseases","status":"RECRUITING","sponsor":"BeOne Medicines","startDate":"2026-03-19","conditions":"Skin Diseases","enrollment":98},{"nctId":"NCT07190222","phase":"PHASE3","title":"Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-09-17","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":942},{"nctId":"NCT07012395","phase":"PHASE2","title":"A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis","status":"RECRUITING","sponsor":"Spyre Therapeutics, Inc.","startDate":"2025-05-27","conditions":"Ulcerative Colitis, Inflammatory Bowel Diseases, Colitis","enrollment":645},{"nctId":"NCT05992935","phase":"PHASE1, PHASE2","title":"Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 and mRNA-1405 to Prevent Norovirus Acute Gastroenteritis in Healthy Adults 18 to 80 Years of Age","status":"RECRUITING","sponsor":"ModernaTX, Inc.","startDate":"2023-08-25","conditions":"Norovirus Acute Gastroenteritis","enrollment":1405},{"nctId":"NCT07235059","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of OJR520 in Healthy Volunteers and Participants With Chronic Kidney Disease","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-11-20","conditions":"Chronic Kidney Disease","enrollment":112},{"nctId":"NCT07190209","phase":"PHASE3","title":"Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-09-16","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":942},{"nctId":"NCT07487909","phase":"PHASE1, PHASE2","title":"A Study of SJP-001 in Comparison With Fexofenadine and Naproxen Administered With Alcohol","status":"COMPLETED","sponsor":"Sen-Jam Pharmaceutical","startDate":"2025-09-30","conditions":"Healthy","enrollment":47},{"nctId":"NCT06698575","phase":"PHASE1","title":"A Study to Assess the Safety, Pharmacokinetics, and Tolerability of ABI-1179 in Healthy Subjects and in Subjects Seropositive for HSV-2 With Recurrent Genital Herpes","status":"COMPLETED","sponsor":"Assembly Biosciences","startDate":"2024-12-08","conditions":"Recurrent Genital Herpes Simplex Type 2","enrollment":103},{"nctId":"NCT06132893","phase":"PHASE2, PHASE3","title":"A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy","status":"RECRUITING","sponsor":"Biohaven Therapeutics Ltd.","startDate":"2024-03-14","conditions":"Focal Epilepsy","enrollment":390},{"nctId":"NCT06468228","phase":"PHASE3","title":"A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa","status":"RECRUITING","sponsor":"AbbVie","startDate":"2024-06-27","conditions":"Hidradenitis Suppurativa","enrollment":1280},{"nctId":"NCT05711394","phase":"PHASE3","title":"A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine","status":"RECRUITING","sponsor":"AbbVie","startDate":"2023-05-01","conditions":"Episodic Migraine","enrollment":450},{"nctId":"NCT07310264","phase":"PHASE1","title":"Research Into the Safety of a New Agent (VT-5006) in People With and Without Parkinson's Disease","status":"RECRUITING","sponsor":"Vertero Therapeutics","startDate":"2025-10-30","conditions":"Healthy Volunteers (HV), Parkinson's Disease (PD)","enrollment":84},{"nctId":"NCT06226883","phase":"PHASE2","title":"A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease","status":"RECRUITING","sponsor":"Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)","startDate":"2024-07-18","conditions":"Inflammatory Bowel Diseases, Crohn's Disease","enrollment":385},{"nctId":"NCT06809400","phase":"PHASE1","title":"A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2025-02-18","conditions":"Parkinson Disease","enrollment":127},{"nctId":"NCT07486115","phase":"PHASE1","title":"A Study to Test How Different Doses of BI 3814916 Are Tolerated by Healthy People","status":"NOT_YET_RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2026-04-07","conditions":"Healthy","enrollment":136},{"nctId":"NCT07483632","phase":"PHASE3","title":"A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS)","status":"NOT_YET_RECRUITING","sponsor":"Biogen","startDate":"2026-11-16","conditions":"Relapsing Forms of Multiple Sclerosis","enrollment":185},{"nctId":"NCT05551273","phase":"PHASE2","title":"Study of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-05-05","conditions":"Hepatitis B, HIV Infections","enrollment":29},{"nctId":"NCT05648968","phase":"PHASE3","title":"A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2022-12-30","conditions":"Warm Autoimmune Hemolytic Anemia (wAIHA)","enrollment":90},{"nctId":"NCT07225621","phase":"PHASE2","title":"Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma","status":"RECRUITING","sponsor":"Alpheus Medical, Inc.","startDate":"2026-01-28","conditions":"Glioblastoma, GBM","enrollment":103},{"nctId":"NCT06995820","phase":"PHASE1","title":"A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-06-06","conditions":"Healthy","enrollment":136},{"nctId":"NCT05492500","phase":"PHASE2","title":"A Study of Ponsegromab in People With Heart Failure","status":"TERMINATED","sponsor":"Pfizer","startDate":"2022-09-26","conditions":"Heart Failure","enrollment":455},{"nctId":"NCT07281937","phase":"PHASE2","title":"A Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities","status":"ACTIVE_NOT_RECRUITING","sponsor":"Verdiva Bio Dev Limited","startDate":"2025-11-25","conditions":"Obesity, Overweight","enrollment":206},{"nctId":"NCT06577766","phase":"PHASE1","title":"A Research Study on How NNC0638-0355, a New Medicine, Works in People Living With Overweight or Obesity","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2024-09-03","conditions":"Obesity, Overweight","enrollment":63},{"nctId":"NCT02947347","phase":"PHASE3","title":"Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma","status":"COMPLETED","sponsor":"Pharmacyclics LLC.","startDate":"2017-01-23","conditions":"Follicular Lymphoma","enrollment":445},{"nctId":"NCT06562907","phase":"PHASE1","title":"Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM)","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-08-28","conditions":"Weight Management","enrollment":134},{"nctId":"NCT05741710","phase":"PHASE1, PHASE2","title":"A Study to Assess the Use of Methylone in the Treatment of PTSD","status":"COMPLETED","sponsor":"Transcend Therapeutics","startDate":"2023-03-01","conditions":"Post Traumatic Stress Disorder","enrollment":79},{"nctId":"NCT05396105","phase":"PHASE2, PHASE3","title":"Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema","status":"ENROLLING_BY_INVITATION","sponsor":"Pharvaris Netherlands B.V.","startDate":"2022-12-28","conditions":"Hereditary Angioedema, Hereditary Angioedema Type I, Hereditary Angioedema Type II","enrollment":150},{"nctId":"NCT06784349","phase":"PHASE1","title":"ALN-APOC3 in Adult Participants With Dyslipidemia","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2025-01-27","conditions":"Dyslipidemia","enrollment":32},{"nctId":"NCT05811351","phase":"PHASE2","title":"A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2023-03-06","conditions":"Geographic Atrophy","enrollment":305},{"nctId":"NCT07058077","phase":"PHASE2, PHASE3","title":"A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-08-21","conditions":"Heterozygous Familial Hypercholesterolemia (HeFH)","enrollment":153},{"nctId":"NCT05797610","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-08-08","conditions":"Primary IgA Nephropathy","enrollment":428},{"nctId":"NCT07218549","phase":"PHASE1","title":"Evaluation of the Safety and Effects of Psychoactive Substances in People With Past Opioid Use","status":"NOT_YET_RECRUITING","sponsor":"Christopher D. Verrico","startDate":"2026-05-01","conditions":"Opioid Use, Substance Use Disorders, Opioid Analgesia","enrollment":72},{"nctId":"NCT07471932","phase":"PHASE1","title":"A Study of LAD106 in Healthy Adult Participants","status":"RECRUITING","sponsor":"Almirall, S.A.","startDate":"2026-02-17","conditions":"Healthy Volunteers","enrollment":93},{"nctId":"NCT06785012","phase":"PHASE2","title":"A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-12-26","conditions":"Depressive Disorder, Major","enrollment":124},{"nctId":"NCT05772546","phase":"PHASE2","title":"Avatrombopag vs. Placebo for CIT in GI Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hanny Al-Samkari, MD","startDate":"2023-11-01","conditions":"Gastrointestinal Cancer, Gastrointestinal Neoplasms, Chemotherapy-Induced Thrombocytopenia","enrollment":60},{"nctId":"NCT06881251","phase":"PHASE2","title":"A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2025-02-26","conditions":"Dermatitis, Atopic","enrollment":256},{"nctId":"NCT06576271","phase":"PHASE1","title":"A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants, Healthy Chinese, and Japanese Participants and CTD-ILD Participants","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-09-02","conditions":"Systemic Lupus Erythematosus","enrollment":142},{"nctId":"NCT07467447","phase":"PHASE2","title":"Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight","status":"RECRUITING","sponsor":"Hudson Biotech","startDate":"2026-02-15","conditions":"Obesity","enrollment":300},{"nctId":"NCT06799000","phase":"PHASE3","title":"A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-01-31","conditions":"Hidradenitis Suppurativa","enrollment":555},{"nctId":"NCT05843643","phase":"PHASE3","title":"Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus","status":"RECRUITING","sponsor":"AbbVie","startDate":"2023-07-19","conditions":"Systemic Lupus Erythematosus","enrollment":1000},{"nctId":"NCT07260669","phase":"PHASE2","title":"A Phase 2 Trial to Investigate Efficacy and Safety of Vipoglanstat in Women With Endometriosis","status":"RECRUITING","sponsor":"Gesynta Pharma AB","startDate":"2025-10-15","conditions":"Endometriosis","enrollment":190},{"nctId":"NCT06234501","phase":"NA","title":"Testing the Efficacy of 100mg Vitamin-B6 Daily for Sensory Reactivity in Autism","status":"RECRUITING","sponsor":"University of Reading","startDate":"2024-11-08","conditions":"Autism","enrollment":40},{"nctId":"NCT06717698","phase":"PHASE2","title":"A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease","status":"RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2024-12-02","conditions":"Chronic Kidney Disease","enrollment":465},{"nctId":"NCT07170917","phase":"PHASE2","title":"Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-11-06","conditions":"Hidradenitis Suppurativa","enrollment":208},{"nctId":"NCT06415383","phase":"PHASE1","title":"The Effects of Vitamin B6 Supplementation on Pain Thresholds and Tolerance","status":"COMPLETED","sponsor":"University of Reading","startDate":"2024-05-30","conditions":"Pain","enrollment":43},{"nctId":"NCT06901531","phase":"PHASE3","title":"A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2025-05-22","conditions":"Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer","enrollment":500},{"nctId":"NCT06470048","phase":"PHASE2","title":"A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-10-09","conditions":"Diffuse Cutaneous Systemic Sclerosis","enrollment":200},{"nctId":"NCT06840392","phase":"PHASE3","title":"A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-03-20","conditions":"Hidradenitis Suppurativa","enrollment":555},{"nctId":"NCT07029568","phase":"PHASE1","title":"A Study to See How Safe a New Medicine (NNC0705-0001) is in Healthy People","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2025-06-13","conditions":"Healthy Volunteers, Chronic Kidney Disease","enrollment":116},{"nctId":"NCT07463196","phase":"PHASE1","title":"A Study Investigating the Safety, Absorption, Elimination, and the Effect on the Immune System of ACI-19764 in Healthy Participants","status":"RECRUITING","sponsor":"AC Immune SA","startDate":"2026-01-28","conditions":"Healthy Participants","enrollment":78},{"nctId":"NCT04314531","phase":"PHASE3","title":"Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2020-07-01","conditions":"Active Psoriatic Arthritis","enrollment":296},{"nctId":"NCT06290934","phase":"PHASE2","title":"Study of GS-1427 in Participants With Moderately to Severely Active Ulcerative Colitis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2024-03-27","conditions":"Ulcerative Colitis","enrollment":228},{"nctId":"NCT06952803","phase":"PHASE3","title":"A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-08-06","conditions":"Prostate Cancer","enrollment":700},{"nctId":"NCT06349473","phase":"PHASE1","title":"A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)","status":"RECRUITING","sponsor":"Equilibra Bioscience LLC","startDate":"2024-05-10","conditions":"Healthy Participants, Hemophilia A, Hemophilia B","enrollment":31},{"nctId":"NCT07038824","phase":"PHASE1, PHASE2","title":"A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping to Evaluate the Safety and Efficacy of ENTR-601-45","status":"RECRUITING","sponsor":"Entrada Therapeutics, Inc.","startDate":"2025-08-30","conditions":"Duchenne Muscular Dystrophy (DMD)","enrollment":24},{"nctId":"NCT06649110","phase":"PHASE1, PHASE2","title":"A Study to Learn About the Treatment LTP001 in Healthy Participants (Part A) and in Participants With PAH (Part B)","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-10-24","conditions":"Healthy Volunteers, Pulmonary Arterial Hypertension","enrollment":232},{"nctId":"NCT06671483","phase":"PHASE3","title":"A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines","status":"RECRUITING","sponsor":"Takeda","startDate":"2025-03-03","conditions":"Psoriatic Arthritis","enrollment":1088},{"nctId":"NCT07250802","phase":"PHASE3","title":"A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis","status":"RECRUITING","sponsor":"Takeda","startDate":"2025-12-04","conditions":"Plaque Psoriasis","enrollment":110},{"nctId":"NCT07037862","phase":"PHASE1, PHASE2","title":"A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping to Evaluate the Safety and Efficacy of ENTR-601-44","status":"RECRUITING","sponsor":"Entrada Therapeutics, Inc.","startDate":"2025-06-30","conditions":"Duchenne Muscular Dystrophy (DMD)","enrollment":24},{"nctId":"NCT06671496","phase":"PHASE3","title":"A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines","status":"RECRUITING","sponsor":"Takeda","startDate":"2025-03-10","conditions":"Psoriatic Arthritis","enrollment":600},{"nctId":"NCT06323928","phase":"PHASE2","title":"A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lundbeck A/S","startDate":"2024-04-01","conditions":"Migraine","enrollment":874},{"nctId":"NCT04381897","phase":"PHASE2","title":"Use of N-Acetylcysteine in the Treatment of Repetitive and Self-Injurious Behaviors in Cornelia de Lange Syndrome","status":"NOT_YET_RECRUITING","sponsor":"Johns Hopkins University","startDate":"2026-08-01","conditions":"Cornelia de Lange Syndrome","enrollment":10},{"nctId":"NCT06066619","phase":"NA","title":"Can Cranberry Juice Enhance the Cognition Accuracy and Alleviate Negative Mental Consequences During Multitasking?","status":"SUSPENDED","sponsor":"University of Florida","startDate":"2024-01-10","conditions":"Stress Response, Multitasking Behavior, Mental Stress","enrollment":126},{"nctId":"NCT05125302","phase":"PHASE3","title":"Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)","status":"RECRUITING","sponsor":"AbbVie","startDate":"2022-01-13","conditions":"Migraine","enrollment":1059},{"nctId":"NCT04873362","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2021-05-04","conditions":"Breast Cancer","enrollment":1188},{"nctId":"NCT07436585","phase":"PHASE1","title":"CGM-Guided Acarbose for Painful Diabetic Neuropathy","status":"COMPLETED","sponsor":"Shifa International Hospital","startDate":"2025-09-01","conditions":"Diabetes, Diabetes Complications, Diabetic Neuropathy","enrollment":170},{"nctId":"NCT07223216","phase":"PHASE1","title":"Study of BMF-650 in Otherwise Healthy Overweight or Obese Adult Participants","status":"RECRUITING","sponsor":"Biomea Fusion Inc.","startDate":"2025-10-23","conditions":"Obesity","enrollment":80},{"nctId":"NCT05691361","phase":"PHASE1, PHASE2","title":"Safety, Tolerability, PK, PD of ADX-324 in Healthy Volunteers and Hereditary Angioedema Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"ADARx Pharmaceuticals, Inc.","startDate":"2022-12-14","conditions":"Hereditary Angioedema","enrollment":53},{"nctId":"NCT07442149","phase":"PHASE1","title":"An Investigational Study to Evaluate the Safety and Tolerability of Single and Multiple Ascending Doses of A-005","status":"COMPLETED","sponsor":"Alumis Inc","startDate":"2024-04-22","conditions":"Healthy Volunteer","enrollment":135},{"nctId":"NCT07444294","phase":"PHASE1","title":"A Single- and Multiple-Ascending Dose Study of SRK-439 in Healthy Adults","status":"RECRUITING","sponsor":"Scholar Rock, Inc.","startDate":"2025-11-21","conditions":"Healthy","enrollment":76},{"nctId":"NCT02932150","phase":"PHASE2","title":"Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2016-11","conditions":"Chronic Hepatitis B","enrollment":150},{"nctId":"NCT04884360","phase":"PHASE3","title":"D9319C00001- 1L OC Mono Global RCT","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-05-31","conditions":"Ovarian Cancer","enrollment":366},{"nctId":"NCT07047703","phase":"PHASE1, PHASE2","title":"EAST-1 (ERAP-inhibition in Axial Spondyloarthritis Trial - 1)","status":"RECRUITING","sponsor":"Grey Wolf Therapeutics","startDate":"2025-07-28","conditions":"Axial Spondyloarthritis (AxSpA)","enrollment":141},{"nctId":"NCT07437105","phase":"PHASE1","title":"Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants","status":"NOT_YET_RECRUITING","sponsor":"Vertex Pharmaceuticals Incorporated","startDate":"2026-02-23","conditions":"Cystic Fibrosis","enrollment":128},{"nctId":"NCT03598309","phase":"PHASE2","title":"Phase II Trial to Modulate Intermediate Endpoint Biomarkers in Former and Current Smokers","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2019-06-05","conditions":"Lung Diseases, Lung Cancer, Protection Against","enrollment":19},{"nctId":"NCT07437560","phase":"PHASE2","title":"Melanotan II (MT-II) as an Adjunct to NB-UVB Phototherapy for Repigmentation in Stable Nonsegmental Vitiligo","status":"RECRUITING","sponsor":"Hudson Biotech","startDate":"2026-02-02","conditions":"NonSegmental Vitiligo, Nonsegmental Vitiligo (Stable)","enrollment":60},{"nctId":"NCT07098988","phase":"PHASE2","title":"Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC","status":"RECRUITING","sponsor":"CatalYm GmbH","startDate":"2025-08-01","conditions":"Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor","enrollment":107},{"nctId":"NCT07140614","phase":"PHASE1","title":"A First in Human Study to Assess the Safety, Tolerability, and Pharmacokinetics of EDK060 in Adults With CMT1A.","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-09-30","conditions":"Charcot-Marie-Tooth Disease, Type 1A","enrollment":28},{"nctId":"NCT07440147","phase":"NA","title":"Effects of Akkermansia Muciniphila and Berberine Supplementation on Insulin Sensitivity in Night-shift Workers","status":"RECRUITING","sponsor":"FH Joanneum Gesellschaft mbH","startDate":"2026-01-20","conditions":"Obesity & Overweight, Circadian Rhythm Disorders, Gut Microbiota Modulation","enrollment":200},{"nctId":"NCT07357766","phase":"PHASE3","title":"A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight","status":"NOT_YET_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2026-06-22","conditions":"Overweight, Obesity","enrollment":1400},{"nctId":"NCT07357740","phase":"PHASE2","title":"A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2026-08-27","conditions":"Diabetes Mellitus, Type 2","enrollment":400},{"nctId":"NCT03631199","phase":"PHASE3","title":"Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2018-12-21","conditions":"Non-small Cell Lung Cancer","enrollment":673}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Matching Placebo (B)","genericName":"Matching Placebo (B)","companyName":"Syntara","companyId":"syntara","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}